The role of edoxaban in preventing thromboembolic complications in patients with atrial fibrillation
Edoxaban is a selective direct factor Xa inhibitor. Edoxaban in a dose of 60 mg per day is an effective and safe option in the prevention of thromboembolic complications in patients with nonvalvular atrial fibrillation, including in combination therapy in patients after percutaneous coronary interve...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«REMEDIUM GROUP» Ltd.
2020-12-01
|
| Series: | Атеротромбоз |
| Subjects: | |
| Online Access: | https://www.aterotromboz.ru/jour/article/view/225 |